BERKELEY

Rokid Will Release a New AR Consumer-Grade Product Based on Spatial Computing

Retrieved on: 
Thursday, February 22, 2024

New York, New York--(Newsfile Corp. - February 22, 2024) - In March 2024, Rokid will release a new AR consumer-grade product based on spatial computing, which is lighter in weight and fully supports 3D content, spatial interaction and 4K high-definition video.

Key Points: 
  • New York, New York--(Newsfile Corp. - February 22, 2024) - In March 2024, Rokid will release a new AR consumer-grade product based on spatial computing, which is lighter in weight and fully supports 3D content, spatial interaction and 4K high-definition video.
  • Weighing only 76 grams, Rokid Max Pro has the spatial interaction capabilities such as gestures and sounds.
  • Fully adapting Google android TV makes Rokid Station becoming the first AR version of the portable Android TV terminal, and inducts Google Play.
  • Rokid Max AR Glasses have excellent configuration including 120HZ refresh rate, 50-degree FOV large viewing angle, and 0-600 degree refractive adjustment.

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024

BERKELEY, Calif., March 11, 2024 (GLOBE NEWSWIRE) --  Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the fourth quarter and full year 2023 and reviewed recent pipeline progress.

Key Points: 
  • “For our lead program, CB-010, we plan to present initial dose expansion data and the RP2D in the second quarter of 2024.
  • For our third program, CB-012, we are thrilled to have recently dosed the first patient in the AMpLify trial.
  • In December 2023, Caribou shared regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type B clinical meeting.
  • CB-012: Caribou plans to provide updates on dose escalation as the AMpLify Phase 1 clinical trial in r/r AML advances.

Senior Business Leader Joins SMU Cox Spears Institute for Entrepreneurial Leadership

Retrieved on: 
Monday, March 11, 2024

Dallas, TX (SMU), March 11, 2024 (GLOBE NEWSWIRE) -- Veteran leader Joshua Taylor has joined SMU Cox School of Business as the Managing Director of the William S. Spears Institute for Entrepreneurial Leadership .

Key Points: 
  • Dallas, TX (SMU), March 11, 2024 (GLOBE NEWSWIRE) -- Veteran leader Joshua Taylor has joined SMU Cox School of Business as the Managing Director of the William S. Spears Institute for Entrepreneurial Leadership .
  • Taylor brings 20 years of experience in senior leadership roles in strategy consulting, Fortune 500 and start-up organizations.
  • Dr. Spears, Founder and Chairman of Cenergistic, launched the Institute in April 2022 with the largest gift by a non-alumnus in the history of SMU.
  • The gift creating the Spears Institute for Entrepreneurial Leadership was a signature moment for SMU Ignited: Boldly Shaping Tomorrow, the University’s $1.5 billion campaign for impact.

New Breakthrough Institute Report Details Pathway for Nuclear Regulatory Commission to Improve Public Engagement

Retrieved on: 
Thursday, March 7, 2024

BERKELEY, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- A new report from the Breakthrough Institute identifies key challenges the Nuclear Regulatory Commission (NRC) faces in engaging the public and provides detailed recommendations for improvement.

Key Points: 
  • BERKELEY, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- A new report from the Breakthrough Institute identifies key challenges the Nuclear Regulatory Commission (NRC) faces in engaging the public and provides detailed recommendations for improvement.
  • Despite recent statements by the NRC that improving public engagement is a priority, substantial barriers remain.
  • The report, titled “Improving Nuclear Regulatory Commission Public Engagement,” provides a well-informed starting point for NRC to better engage the public.
  • That is why the detailed feedback in this report, based on substantial engagement with the NRC, is so valuable.”
    To read the full report, click here .

Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, March 5, 2024

BERKELEY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that preclinical data from CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML), will be presented as a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10, 2024 in San Diego.

Key Points: 
  • BERKELEY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that preclinical data from CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML), will be presented as a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10, 2024 in San Diego.
  • Details of the poster presentation are as follows:
    Title: Preclinical evaluation of CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy, that exhibits specific and potent cytotoxicity in acute myeloid leukemia (AML) xenograft models
    The poster will be available on the Scientific Publications page of Caribou’s website on Tuesday, April 9, 2024 at 1:30 pm PT.

Rigetti Computing to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 14, 2024

Retrieved on: 
Monday, March 4, 2024

BERKELEY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. ("Rigetti" or the "Company") (Nasdaq: RGTI), a pioneer in hybrid quantum-classical computing, announced today that it will release fourth quarter and full year 2023 results on Thursday, March 14, 2024 after market close.

Key Points: 
  • BERKELEY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. ("Rigetti" or the "Company") (Nasdaq: RGTI), a pioneer in hybrid quantum-classical computing, announced today that it will release fourth quarter and full year 2023 results on Thursday, March 14, 2024 after market close.
  • The Company will host a conference call to discuss its financial results and provide an update on its business operations at 5:00 p.m.
  • A replay of the conference call will be available at the same locations following the conclusion of the call for one year.
  • If you register and forget your PIN, or lose the registration confirmation email, simply re-register to receive a new PIN.

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Retrieved on: 
Monday, March 4, 2024

FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics.

Key Points: 
  • FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics.
  • We expect his financial strategy and business development expertise from working with development and commercial stage public companies to be a critical asset as we execute our clinical, regulatory and commercialization plans,” said Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics.
  • Prior to Aeovian, he was Chief Financial Officer at Imago Biosciences (acquired by Merck), where he led the efforts for the company’s $155 million Nasdaq initial public offering (IPO).
  • He was previously Chief Financial Officer at Nkarta Therapeutics, where he led the efforts for its $290 million Nasdaq IPO.

Carol MacKinlay Joins Tech CU’s Board of Directors

Retrieved on: 
Thursday, February 29, 2024

SAN JOSE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Today, Tech CU (Technology Credit Union) announced the appointment of Carol MacKinlay to its Board of Directors.

Key Points: 
  • SAN JOSE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Today, Tech CU (Technology Credit Union) announced the appointment of Carol MacKinlay to its Board of Directors.
  • With over 30 years of experience in executive leadership roles, Carol brings a wealth of expertise in human resources, corporate governance, and fostering organizational excellence.
  • "We are thrilled to welcome Carol to our Board of Directors," said Todd Harris, the CEO at Tech CU.
  • In addition to serving on the Tech CU board, Carol serves on the boards of Exodus and Nitro Workforce Solutions.

Riverlane and Rigetti Computing Partner with Oak Ridge National Laboratory to Work to Improve HPC-Quantum Integration

Retrieved on: 
Tuesday, February 27, 2024

As the performance of quantum computers improves, their integration with high-performance computing (HPC) to tackle complex computing challenges will become commonplace.

Key Points: 
  • As the performance of quantum computers improves, their integration with high-performance computing (HPC) to tackle complex computing challenges will become commonplace.
  • We believe the result will be the ability to solve problems for society that are unsolvable today.
  • “This project aims to move us ahead in making quantum computing devices both more practical in general and more interoperable with HPC systems.
  • “Integrating quantum processors with modern HPC is an important next step in the evolution of both quantum computing and HPC.

New UC Berkeley Center Aims to Create Healthcare Innovation Research-to-Impact Pipeline

Retrieved on: 
Wednesday, March 6, 2024

Developing and using the research on healthcare innovation incentives will lead to the creation and deployment of interventions that meaningfully improve public health.

Key Points: 
  • Developing and using the research on healthcare innovation incentives will lead to the creation and deployment of interventions that meaningfully improve public health.
  • The new Berkeley center aims to play an essential role in ensuring those innovations benefit the public.
  • The center aims to connect expertise in behavioral economics with advanced research and development at Berkeley to help develop healthcare solutions that people and companies want and will harness.
  • “I’m very excited to see some of Berkeley’s great minds and cutting-edge resources come together at the new Center for Healthcare Marketplace Innovation.”